Clofarabine-based Therapy

Clofarabine-Based Therapy is a chemotherapeutic regimen defined by the inclusion of clofarabine, a nucleoside analog inhibitor of DNA synthesis and ribonucleotide reductase, as the principal cytotoxic agent in the treatment of refractory childhood cancers.

266

Publications

16.4K

Citations

1.7K

Authors

613

Institutions

Publications per year

2017–2026

36

Authors

1.7K

  1. HM
    Hagop M. Kantarjian

    The University of Texas MD Anderson Cancer Center, United States

    43 publications · 4K citations

    27

    h-index

  2. MJ
    Michael J. Keating

    The University of Texas MD Anderson Cancer Center, United States

    23 publications · 4.4K citations

    21

    h-index

  3. SF
    Stefan Faderl

    The University of Texas MD Anderson Cancer Center, United States

    24 publications · 1.8K citations

    17

    h-index

  4. VG
    Varsha Gandhi

    The University of Texas MD Anderson Cancer Center, United States

    19 publications · 1.6K citations

    16

    h-index

  5. WP
    William Plunkett

    The University of Texas MD Anderson Cancer Center, United States

    18 publications · 1.8K citations

    16

    h-index

1–5 of 1.7K

Venues

  1. Blood

    55 publications · 5.8K citations

    27

    h-index

  2. PubMed

    Repository · 19 publications · 922 citations

    15

    h-index

  3. Journal of Clinical Oncology

    16 publications · 1.8K citations

    14

    h-index

  4. British Journal of Haematology

    BJH · 12 publications · 547 citations

    12

    h-index

  5. Leukemia & lymphoma/Leukemia and lymphoma

    15 publications · 423 citations

    12

    h-index

1–5